
|Videos|July 29, 2013
Potential Cost Savings of Biosimilars
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
Advertisement
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
For more videos featuring Debbie Stern, please click on our
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
American Regent Recalls 3 Epinephrine Injection Lots Over Particulate Matter, Sterility Concerns
2
As Measles Cases Surge, Pharmacists Are Stepping Up to Close the Vaccination Gap
3
Building a Strong Financial Foundation: 5 Pillars Every Pharmacist Needs Before Optimizing Their Financial Plan
4
High-Dose Influenza Vaccine Lowers Hospitalization Risk in Older Adults With Chronic Lung Disease
5





































































































